GLP-1
WEIGHT MANAGEMENTQuick Specifications
| Vial Size | 24MG |
|---|---|
| BAC Water | 2.4ML |
| Amount Per Unit | 0.1MG PER UNIT |
| Recommended Dose | TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS) |
| Frequency | 1X PER WEEK |
| Injection Type | SUBCUTANEOUS |
| Timing | Same Day Every Week / Starting Dose Is 2 MG |
Research Overview
GLP-3 class peptides are triple receptor agonists targeting GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activation to the dual GLP-1/GIP mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. The three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. Phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. Phase 3 data has since reported up to 28.7% weight loss. The glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. Gastrointestinal tolerability is generally comparable to dual agonists. For research and educational purposes only. Independent purity testing warning (June 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per Chainalysis reporting. Source only from vendors providing current, batch-specific HPLC certificates of analysis.
How It Works
Pancreatic Beta Cell Action
GLP-1 binds receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion — insulin release only occurs when blood glucose is elevated, making hypoglycemia risk lower than with traditional insulin sensitizers.
Hypothalamic Appetite Suppression
GLP-1 receptors in the brain's hypothalamus and brainstem receive signals that reduce appetite and increase satiety. Research now confirms that brain-mediated appetite suppression — not pancreatic action — is the primary driver of GLP-1's weight loss effects.
Gastric Emptying Delay
By slowing the rate at which food leaves the stomach, GLP-1 reduces the speed of glucose absorption into the bloodstream and prolongs the sensation of fullness. This mechanism also accounts for nausea experienced during early dose titration.
Commonly Studied With
These peptides are frequently researched alongside Retatrutide (GLP-1/GIP/Glucagon): 24mg due to complementary mechanisms:
Affiliate disclosure: Peptide Hub may earn a commission on purchases made through these links at no cost to you.
Research references
The following PubMed resources are provided for educational reference. External links open in a new tab.
Retatrutide (GLP-1/GIP/Glucagon): 24mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS)